Sheffield Arthritis And Muscle Pain Relief
Capsicum Oleoresin
Sheffield Pharmaceuticals Llc
Human Otc Drug
NDC 11527-089Sheffield Arthritis And Muscle Pain Relief also known as Capsicum Oleoresin is a human otc drug labeled by 'Sheffield Pharmaceuticals Llc'. National Drug Code (NDC) number for Sheffield Arthritis And Muscle Pain Relief is 11527-089. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Sheffield Arthritis And Muscle Pain Relief drug includes Capsicum Oleoresin - .25 mg/g . The currest status of Sheffield Arthritis And Muscle Pain Relief drug is Active.
Drug Information:
| Drug NDC: | 11527-089 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Sheffield Arthritis And Muscle Pain Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Capsicum Oleoresin |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Sheffield Pharmaceuticals Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Cream |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAPSICUM OLEORESIN - .25 mg/g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 14 Apr, 2010 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 07 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Sheffield Pharmaceuticals LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 198555
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | UW86K581WY
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 11527-089-54 | 1 TUBE in 1 CARTON (11527-089-54) / 43 g in 1 TUBE | 14 Apr, 2010 | N/A | No |
| 11527-089-60 | 1 TUBE in 1 CARTON (11527-089-60) / 60 g in 1 TUBE | 22 Dec, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose
Product Elements:
Sheffield arthritis and muscle pain relief capsicum oleoresin sorbitol water isopropyl myristate cetyl alcohol glyceryl monostearate peg-100 stearate benzyl alcohol petrolatum paraffin capsicum oleoresin capsicum oleoresin capsicum
Indications and Usage:
Uses for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis,strains,bruises and sprains
Warnings:
Warnings for external use only avoid contact with the eyes and mucous membranes if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days, discontinue use of this product and consult a doctor. do not apply to wounds or damaged skin. do not bandage tightly. do not use with a heating pad or on wounds, damaged, broken (open) or irritated skin. discontinue use if excessive irritation of skin develops. if pregnant or breast feeding, ask a health professional before use. a temporary burning sensation may occur upon application, but generally disappears in a few days keep this and all drugs out of the reach of children. if swallowed, get medical help or contact a poison control center immediately directions adults and children 2 years of age and older: apply to the affected area not more than 3 to 4 times daily. children under 2 years of age: consult a doctor. unless treating hands, wash thoroughly with soap and water immediately after use
Read more....
Dosage and Administration:
Other information store at controlled room temperature 20°- 25°c (68° - 77°f) close the cap tightly after use
Package Label Principal Display Panel:
Principal display panel â 60 g carton label sheffield ndc 11527-089-60 made in the usa arthritis & muscle pain relief cream topical analgesic net wt. 60g (2.11oz) principal display panel â 60g carton label
Principal display panel â 60g tube label sheffield ndc 11527-089-60 made in the usa arthritis & muscle pain relief cream topical analgesic net wt. 60g (2.11oz) principal display panel â 60g tube label